Form 4: Alnylam Director Charles Elliott Sigal Acquires Shares Via Stock Option Grant

Director Charles Elliott Sigal reports acquisition of 5,228 shares of Alnylam Pharmaceuticals via stock option grant.

Summary

• Charles Elliott Sigal, a director of Alnylam Pharmaceuticals, acquired 5,228 shares of common stock through a stock option grant on May 16, 2024.
• The exercise price of the stock option is $151.22.
• The options vest in full on the earlier of the first anniversary of the grant date (May 16, 2025) or the date of retirement or resignation, provided such date occurs no more than 90 days prior to the first anniversary.
• Following the transaction, Sigal directly owns 5,228 shares.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document reports a routine stock option grant to a director. It doesn't contain information that would significantly sway investor sentiment positively or negatively.

Positives

• A director's acquisition of shares can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the options suggests a continued relationship between the director and the company for at least one year.

Industry Context

Insider transactions are common in the pharmaceutical industry and are closely monitored by investors for signals about a company's prospects. Option grants are a typical form of executive compensation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation plans.
• The vesting schedules and exercise prices are typically benchmarked against industry standards to align executive incentives with shareholder value creation.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's performance.

Key Dates